Загрузка...
Cervical cancer – State of the science: From angiogenesis blockade to checkpoint inhibition
Vascular endothelial growth factor (VEGF) has emerged as a therapeutic target in several malignancies, including cervical cancer. Chemotherapy doublets combined with the fully humanized monoclonal antibody, bevacizumab, now constitute first-line therapy for women struggling with recurrent/metastatic...
Сохранить в:
| Опубликовано в: : | Gynecol Oncol |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6720107/ https://ncbi.nlm.nih.gov/pubmed/29666026 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2018.01.009 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|